Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-18038683 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| JNJ-18038683 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Escitalopram | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Form= capsule, route= oral use. Administration once daily for 8 weeks. |
| Escitalopram | DRUG | Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week. |
| JNJ-18038683 | DRUG | Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week. |
Inclusion Criteria: * Diagnosed with moderate to severe major depressive disorder * Willing to use acceptable methods of birth control throughout the study and for 3 months after * In good general health Exclusion Criteria: * No history or current diagnosis of other psychiatric conditions such as...
Top 20 of 29 competitors
JNJ-18038683 is an investigational small molecule being studied for the treatment of Major Depressive Disorder. It is in Phase 2 clinical development and has been evaluated in a completed clinical trial involving patients with moderate to severe depression.
JNJ-18038683 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is currently in Phase 2 clinical development for Major Depressive Disorder.
JNJ-18038683 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial for the drug has been completed.
JNJ-18038683 has been studied in one completed Phase 2 clinical trial, identified as NCT00566202. This trial was a randomized, double-blind, placebo-controlled study that enrolled 67 participants with Major Depressive Disorder in the United States.
JNJ-18038683 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Major Depressive Disorder. Its safety and effectiveness have not been established, and it remains under clinical investigation.